glp-1 obesity drug news today 2025-10-20 trends 2025: real-world data, patient outcomes & future therapies Hims & Hers Health stock

Description

GDMT for HFrEF typically includes evidence-based beta-blockers, angiotensin receptor neprilysin inhibitors (ARNIs), angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2is), particularly in patients with obesity or T2DM [53]

Article information 2

The Rise of Compounded GLP-1 Drugs If brand-name drugs come with risks, the situation becomes even murkier when compounded medications enter the picture

These findings provide evidence that the regulatory influence of endogenous GLP-1R signaling on bone resorption is likely mediated through pathways that involve calcitonin